Entegris R&D decreased by 4.7% to $75.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.2%, from $84.80M to $75.30M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 18.4% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $41.97M | $41.97M | $45.94M | $46.72M | $49.25M | $64.99M | $68.04M | $71.91M | $71.03M | $66.81M | $67.55M | $71.80M | $81.90M | $80.90M | $81.50M | $84.80M | $84.30M | $80.90M | $79.00M | $75.30M |
| QoQ Change | — | +0.0% | +9.5% | +1.7% | +5.4% | +32.0% | +4.7% | +5.7% | -1.2% | -5.9% | +1.1% | +6.3% | +14.1% | -1.2% | +0.7% | +4.0% | -0.6% | -4.0% | -2.3% | -4.7% |
| YoY Change | — | — | — | — | +17.3% | +54.8% | +48.1% | +53.9% | +44.2% | +2.8% | -0.7% | -0.1% | +15.3% | +21.1% | +20.6% | +18.1% | +2.9% | +0.0% | -3.1% | -11.2% |
Range$41.97M – $84.80M
CAGR+13.1%
Avg YoY Growth+17.8%
Median YoY Growth+16.3%
Current Streak4 quarters decline
R&D at Other Companies
Frequently Asked Questions
- What is Entegris's r&d?
- Entegris (ENTG) reported r&d of $75.30M in Q1 2026.
- How has Entegris's r&d changed year-over-year?
- Entegris's r&d decreased by 11.2% year-over-year, from $84.80M to $75.30M.
- What is the long-term trend for Entegris's r&d?
- Over 4 years (2021 to 2025), Entegris's r&d has grown at a 18.4% compound annual growth rate (CAGR), from $167.63M to $329.00M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.